Immunothearpy for the Treatment of Multiple Myeloma

Le Ray E, Jagannath S, Palumbo A. Advances in targeted therapy for the treatment of patients with relapsed/refractory multiple myeloma. Expert Rev Hematol. 2016;9(1):91-105.

Raza S, Safyan RA, Lentzsch S. Immunomodulatory Drugs (IMiDs) in Multiple Myeloma. Curr Cancer Drug Targets. 2017;17(9):846-857

Usmani S, Ahmadi T, Ng Y, Lam A, Desai A, Potluri R, Mehra M. Analysis of Real-World Data on Overall Survival in Multiple Myeloma Patients With ≥3 Prior Lines of Therapy Including a Proteasome Inhibitor (PI) and an Immunomodulatory Drug (IMiD), or Double Refractory to a PI and an IMiD. Oncologist. 2016;21(11):1355-1361.

Kazmi SM, Nusrat M, Gunaydin H, Cornelison AM, Shah N, Kebriaei P, Nieto Y, Parmar S, Popat UR, Oran B, Shah JJ, Orlowski RZ, Champlin RE, Qazilbash MH, Bashir Q. Outcomes Among High-Risk and Standard-Risk Multiple Myeloma Patients Treated With High-Dose Chemotherapy and Autologous Hematopoietic Stem-Cell Transplantation. Clin Lymphoma Myeloma Leuk. 2015;15(11):687-93.

Boussi LS, Avigan ZM, Rosenblatt J. Immunotherapy for the treatment of multiple myeloma. Front Immunol. 2022;13:1027385.

Bird JM, Russell NH, Samson D. Minimal residual disease after bone marrow transplantation for multiple myeloma: evidence for cure in long-term survivors. Bone Marrow Transplant. (1993) 12(6):651–4.

Lokhorst HM, Schattenberg A, Cornelissen JJ, van Oers MH, Fibbe W, Russell I, et al. Donor lymphocyte infusions for relapsed multiple myeloma after allogeneic stem-cell transplantation: predictive factors for response and long-term outcome. J Clin Oncol (2000) 18(16):3031–7.

Tricot G, Vesole DH, Jagannath S, Hilton J, Munshi N, Barlogie B. Graft-versus-myeloma effect: proof of principle. Blood. 1996 Feb 1;87(3):1196-8.

Dhakal B, Vesole DH, Hari PN. Allogeneic stem cell transplantation for multiple myeloma: is there a future? Bone Marrow Transplant (2016) 51(4):492–500.

Giralt S, Garderet L, Durie B et al. American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma. Biol Blood Marrow Transplant. 2015 Dec;21(12):2039-2051.

Leleu X, Martin T, Weisel K, Schjesvold F, Iida S, Malavasi F, Manier S, Chang-Ki Min, Ocio EM, Pawlyn C, Perrot A, Quach H, Richter J, Spicka I, Yong K, Richardson PG. Anti-CD38 antibody therapy for patients with relapsed/refractory multiple myeloma: differential mechanisms of action and recent clinical trial outcomes. Ann Hematol. 2022 Oct;101(10):2123-2137.

Barr H, Dempsey J, Waller A, Huang Y, Williams N, Sharma N, Benson DM, Rosko AE, Efebera YA, Hofmeister CC. Ninety-minute daratumumab infusion is safe in multiple myeloma. Leukemia. 2018 Nov;32(11):2495-2518.

Gozzetti A, Bacchiarri F, Sammartano V, Defina M, Sicuranza A, Mecacci B, Zappone E, Cencini E, Fabbri A, Raspadori D, Bocchia M. Long-Term Safety of Rapid Daratumumab Infusions in Multiple Myeloma Patients. Front Oncol. 2020 Dec 21;10:570187.

Minakata D, Fujiwara SI, Yokoyama D, Noguchi A, Aoe S, Oyama T, Koyama S, Murahashi R, Nakashima H, Hyodo K, Ikeda T, Kawaguchi SI, Toda Y, Ito S, Nagayama T, Mashima K, Umino K, Morita K, Ashizawa M, Yamamoto C, Hatano K, Sato K, Ohmine K, Kanda Y. Relapsed and refractory multiple myeloma: A systematic review and network meta-analysis of the efficacy of novel therapies. Br J Haematol. 2023 Mar;200(6):694-703.

Tauseef A, Zafar M, Silberstein P, Nahas J, Frederickson T, Abodunrin F, Abbas A, Arshad W, Lateef N, Rangoonwala H, Albagoush S, Mirza M. Role of daratumumab in relapsed or refractory multiple myeloma patient: A meta-analysis and literature to review. J Family Med Prim Care. 2022 Jun;11(6):2648-2655.

Jakubowiak AJ, Kumar S, Medhekar R, Pei H, Lefebvre P, Kaila S, He J, Lafeuille MH, Cortoos A, Londhe A, Mavros P, Lin TS, Usmani SZ. Daratumumab Improves Depth of Response and Progression-free Survival in Transplant-ineligible, High-risk, Newly Diagnosed Multiple Myeloma. Oncologist. 2022 Jul 5;27(7):e589-e596.

Botta C, Gigliotta E, Paiva B, et al. Network meta-analysis of randomized trials in multiple myeloma: efficacy and safety in frontline therapy for patients not eligible for transplant. Hematol Oncol. 2022; 40(5): 987-998.

Nooka AK, Gleason C, Sargeant MO, Walker M, Watson M, Panjic EH, Lonial S. Managing Infusion Reactions to New Monoclonal Antibodies in Multiple Myeloma: Daratumumab and Elotuzumab. J Oncol Pract. 2018 Jul;14(7):414-422.

Jiang H, Acharya C, An G, Zhong M, Feng X, Wang L, Dasilva N, Song Z, Yang G, Adrian F, Qiu L, Richardson P, Munshi NC, Tai YT, Anderson KC. SAR650984 directly induces multiple myeloma cell death via lysosomal-associated and apoptotic pathways, which is further enhanced by pomalidomide. Leukemia. 2016 Feb;30(2):399-408.

Delgado J, Zienowicz M, van Hennik PB, Moreau A, Gisselbrecht C, Enzmann H, Pignatti F. EMA Review of Isatuximab in Combination with Pomalidomide and Dexamethasone for the Treatment of Adult Patients with Relapsed and Refractory Multiple Myeloma. Oncologist. 2021 Nov;26(11):983-987.

Attal M, Richardson PG, Rajkumar SV, San-Miguel J, Beksac M, Spicka I, Leleu X, Schjesvold F, Moreau P, Dimopoulos MA, Huang JS, Minarik J, Cavo M, Prince HM, Macé S, Corzo KP, Campana F, Le-Guennec S, Dubin F, Anderson KC; ICARIA-MM study group. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study. Lancet. 2019 Dec 7;394(10214):2096-2107.

Moreau P, Dimopoulos MA, Mikhael J, Yong K, Capra M, Facon T, Hajek R, Špička I, Baker R, Kim K, Martinez G, Min CK, Pour L, Leleu X, Oriol A, Koh Y, Suzuki K, Risse ML, Asset G, Macé S, Martin T; IKEMA study group. Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial. Lancet. 2021 Jun 19;397(10292):2361-2371.

Quach H, Parmar G, Ocio EM, Prince HM, Oriol A, Tsukada N, Sunami K, Bories P, Karanes C, Madan S, Semiond D, Inchauspe M, Macé S, Musholt PB, Suzan F, Moreau P. P945: subcutaneous ısatuxımabadmınıstratıon by an on-body delıvery system ıncombınatıonwıthpomalıdomıde-dexamethasone ın relapsed/refractory multıple myeloma patıents: ınterım phase 1b study results. hemasphere. 2022 jun 23;6(suppl ):835-836.

Ishida T. Therapeutic antibodies for multiple myeloma. Jpn J Clin Oncol. 2018 Nov 1;48(11):957-963.

Tai YT, Soydan E, Song W, Fulciniti M, Kim K, Hong F, Li XF, Burger P, Rumizen MJ, Nahar S, Podar K, Hideshima T, Munshi NC, Tonon G, Carrasco RD, Afar DE, Anderson KC. CS1 promotes multiple myeloma cell adhesion, clonogenic growth, and tumorigenicity via c-maf-mediated interactions with bone marrow stromal cells. Blood. 2009 Apr 30;113(18):4309-18.

Hsi ED, Steinle R, Balasa B, Szmania S, Draksharapu A, Shum BP, Huseni M, Powers D, Nanisetti A, Zhang Y, Rice AG, van Abbema A, Wong M, Liu G, Zhan F, Dillon M, Chen S, Rhodes S, Fuh F, Tsurushita N, Kumar S, Vexler V, Shaughnessy JD Jr, Barlogie B, van Rhee F, Hussein M, Afar DE, Williams MB. CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma. Clin Cancer Res. 2008 May 1;14(9):2775-84.

Audie Rice, Myles Dillon, Anne van Abbema, Lynne Jesaitis, Melanie Wong, Stacey Lawson, Gao Liu, Yin Zhang, David Powers, Susan Rhodes, Ingrid Caras, Debbie Law, Daniel Afar.Erdication of Tumors in Pre-Clinical Models of Multiple Myeloma by Anti-CS1 Monoclonal Antibody HuLuc63: Mechanism of Action Studies.,Blood,Volume 108, Issue 1.

van Rhee F, Szmania SM, Dillon M, van Abbema AM, Li X, Stone MK, Garg TK, Shi J, Moreno-Bost AM, Yun R, Balasa B, Ganguly B, Chao D, Rice AG, Zhan F, Shaughnessy JD Jr, Barlogie B, Yaccoby S, Afar DE. Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma. Mol Cancer Ther. 2009 Sep;8(9):2616-24.

Balasa B, Yun R, Belmar NA, Fox M, Chao DT, Robbins MD, Starling GC, Rice AG. Elotuzumab enhances natural killer cell activation and myeloma cell killing through interleukin-2 and TNF-α pathways. Cancer Immunol Immunother. 2015 Jan;64(1):61-73.

Wang Y, Sanchez L, Siegel DS, Wang ML. Elotuzumab for the treatment of multiple myeloma. J Hematol Oncol. 2016 Jul 15;9(1):55.

Dimopoulos MA, Dytfeld D, Grosicki S, Moreau P, Takezako N, Hori M, Leleu X, LeBlanc R, Suzuki K, Raab MS, Richardson PG, Popa McKiver M, Jou YM, Yao D, Das P, San-Miguel J. Elotuzumab Plus Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma: Final Overall Survival Analysis From the Randomized Phase II ELOQUENT-3 Trial. J Clin Oncol. 2023 Jan 20;41(3):568-578.

Yu J, Song Y, Tian W. How to select IgG subclasses in developing anti-tumor therapeutic antibodies. J Hematol Oncol. 2020 May 5;13(1):45.

Sheyi R, de la Torre BG, Albericio F. Linkers: An Assurance for Controlled Delivery of Antibody-Drug Conjugate. Pharmaceutics. 2022 Feb 11;14(2):396.

O’Connor BP, Raman VS, Erickson LD, Cook WJ, Weaver LK, Ahonen C, Lin LL, Mantchev GT, Bram RJ, Noelle RJ. BCMA is essential for the survival of long-lived bone marrow plasma cells. J Exp Med. 2004 Jan 5;199(1):91-8.

Eckhert, Erik, Rhonda Hewitt, and Michaela Liedtke. “B-cell maturation antigen directed monoclonal antibody therapies for multiple myeloma.” Immunotherapy 11.9 (2019): 801811.

Bellucci R, Alyea EP, Chiaretti S, Wu CJ, Zorn E, Weller E, Wu B, Canning C, Schlossman R, Munshi NC, Anderson KC, Ritz J. Graft-versus-tumor response in patients with multiple myeloma is associated with antibody response to BCMA, a plasma-cell membrane receptor. Blood. 2005 May 15;105(10):3945-50.

Darce JR, Arendt BK, Wu X, Jelinek DF. Regulated expression of BAFF-binding receptors during human B cell differentiation. J Immunol. 2007 Dec 1;179(11):7276-86.

Lee L, Bounds D, Paterson J, Herledan G, Sully K, Seestaller-Wehr LM, Fieles WE, Tunstead J, McCahon L, Germaschewski FM, Mayes PA, Craigen JL, Rodriguez-Justo M, Yong KL. Evaluation of B cell maturation antigen as a target for antibody drug conjugate mediated cytotoxicity in multiple myeloma. Br J Haematol. 2016 Sep;174(6):911-22.

Tai YT, Acharya C, An G, Moschetta M, Zhong MY, Feng X, Cea M, Cagnetta A, Wen K, van Eenennaam H, van Elsas A, Qiu L, Richardson P, Munshi N, Anderson KC. APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment. Blood. 2016 Jun 23;127(25):3225-36.

Bolkun L, Lemancewicz D, Jablonska E, Kulczynska A, Bolkun-Skornicka U, Kloczko J, Dzieciol J. BAFF and APRIL as TNF superfamily molecules and angiogenesis parallel progression of human multiple myeloma. Ann Hematol. 2014 Apr;93(4):635-44.

Yaccoby S, Pennisi A, Li X, Dillon SR, Zhan F, Barlogie B, Shaughnessy JD Jr. Atacicept (TACI-Ig) inhibits growth of TACI(high) primary myeloma cells in SCID-hu mice and in coculture with osteoclasts. Leukemia. 2008 Feb;22(2):406-13.

Liang Lin, Shih-Feng Cho, Kenneth Wen, Tengteng Yu, Phillip A Hsieh, Yuyin Li, Gang An, Lugui Qiu, Nikhil C. Munshi, Kenneth C. Anderson, Yu-Tzu Tai; Impacts of a Proliferation-Inducing Ligand on Current Therapeutic Monoclonal Antibody-Induced Cytotoxicity Against Human Multiple Myeloma Cells. Blood 2019; 134 (Supplement_1): 3105.

Demchenko YN, Glebov OK, Zingone A, Keats JJ, Bergsagel PL, Kuehl WM. Classical and/or alternative NF-kappaB pathway activation in multiple myeloma. Blood. 2010 Apr 29;115(17):3541-52.

Hua H, Kong Q, Zhang H, Wang J, Luo T, Jiang Y. Targeting mTOR for cancer therapy. J Hematol Oncol. 2019 Jul 5;12(1):71.

Laurent SA, Hoffmann FS, Kuhn PH, Cheng Q, Chu Y, Schmidt-Supprian M, Hauck SM, Schuh E, Krumbholz M, Rübsamen H, Wanngren J, Khademi M, Olsson T, Alexander T, Hiepe F, Pfister HW, Weber F, Jenne D, Wekerle H, Hohlfeld R, Lichtenthaler SF, Meinl E. γ-Secretase directly sheds the survival receptor BCMA from plasma cells. Nat Commun. 2015 Jun 11;6:7333.

Michael Ghermezi, Mingjie Li, Suzie Vardanyan, Nika Manik Harutyunyan, Jillian Gottlieb, Ariana Berenson, Tanya M. Spektor, Claudia Andreu-Vieyra, Sophia Petraki, Eric Sanchez, Kyle Udd, Cathy S. Wang, Regina A. Swift, Haiming Chen, James R. Berenson. Serum B-cell maturation antigen: a novel biomarker to predict outcomes for multiple myeloma patients. Haematologica 2017;102(4):785-795;

Baines AC, Ershler R, Kanapuru B, Xu Q, Shen G, Li L, Ma L, Okusanya OO, Simpson NE, Nguyen W, Theoret MR, Pazdur R, Gormley NJ. FDA Approval Summary: BelantamabMafodotin for Patients with Relapsed or Refractory Multiple Myeloma. Clin Cancer Res. 2022 Nov 1;28(21):4629-4633.

Lonial S, Lee HC, Badros A, Trudel S, Nooka AK, Chari A, Abdallah AO, Callander N, Lendvai N, Sborov D, Suvannasankha A, Weisel K, Karlin L, Libby E, Arnulf B, Facon T, Hulin C, Kortüm KM, Rodríguez-Otero P, Usmani SZ, Hari P, Baz R, Quach H, Moreau P, Voorhees PM, Gupta I, Hoos A, Zhi E, Baron J, Piontek T, Lewis E, Jewell RC, Dettman EJ, Popat R, Esposti SD, Opalinska J, Richardson P, Cohen AD. Belantamabmafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. Lancet Oncol. 2020 Feb;21(2):207-221.

Dimopoulos MA, Hungria VTM, Radinoff A, Delimpasi S, Mikala G, Masszi T, Li J, Capra M, Maiolino A, Pappa V, Chraniuk D, Osipov I, Leleu X, Low M, Matsumoto M, Sule N, Li M, McKeown A, He W, Bright S, Currie B, Perera S, Boyle J, Roy-Ghanta S, Opalinska J, Weisel K. Efficacy and safety of single-agent belantamabmafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): a phase 3, open-label, randomised study. Lancet Haematol. 2023 Oct;10(10):e801-e812.

Rajshekhar Chakraborty, Ying Yan, Mike Royal; A Phase 1, Open-Label, Dose-Escalation Study of the Safety and Efficacy of Anti-CD38 Antibody Drug Conjugate (STI-6129) in Patients with Relapsed or Refractory Multiple Myeloma. Blood 2021; 138 (Supplement 1): 4763.

Gurpanna Saggu, Min Young Lee, Faith Dunbar, Reshma Singh, Kris Sachsenmeier, Dan T. Vogl, Shebli Atrash, Sarah A. Holstein, Omar Nadeem, Jonathan L. Kaufman, Adarsh Joshi, Kaveri Suryanarayan, Sabrina Collins; Modakafusp Alfa Demonstrates Type I Interferon-Mediated Innate and Adaptive Immune Enhancement in a Phase 1/2 Study in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM). Blood 2023; 142 (Supplement 1): 3316

BhagirathbhaiDholaria, Admasu Mamuye, Diana Yurewicz, Kristina Dabovic, Amy Yuet, Rafat Abonour, Kevin R. Kelly, Timothy J. Voorhees, Dickran Kazandjian; A Phase 1, Open-Label, Dose-Escalation and Expansion, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of MT-0169 in Patients with Relapsed or Refractory Multiple Myeloma or Non-Hodgkin Lymphoma. Blood 2022; 140 (Supplement 1): 12621–12622.

Kennedy VE, Wong C, Huang C-Y, et al. Macrophage activation syndrome-like (MAS-L) manifestations following BCMA-directed CAR T cells in multiple myeloma. Blood Adv. 2021;5(23):5344-5348. Blood Adv. 2023 Jul 25;7(14):3540. doi: 10.1182/bloodadvances.2023010575. Erratum for: Blood Adv. 2021 Dec 14;5(23):5344-53.

Kelly KR, Ailawadhi S, Siegel DS, Heffner LT, Somlo G, Jagannath S, Zimmerman TM, Munshi NC, Madan S, Chanan-Khan A, Lonial S, Chandwani S, Minasyan A, Ruehle M, Barmaki-Rad F, Abdolzade-Bavil A, Rharbaoui F, Herrmann-Keiner E, Haeder T, Wartenberg-Demand A, Anderson KC. Indatuximabravtansine plus dexamethasone with lenalidomide or pomalidomide in relapsed or refractory multiple myeloma: a multicentre, phase 1/2a study. Lancet Haematol. 2021 Nov;8(11):e794-e807.

Zhang M, Wei G, Zhou L, Zhou J, Chen S, Zhang W, Wang D, Luo X, Cui J, Huang S, Fu S, Zhou X, Tang Y, Ding X, Kuang J, He XP, Hu Y, Huang H. GPRC5D CAR T cells (OriCAR-017) in patients with relapsed or refractory multiple myeloma (POLARIS): a first-in-human, single-centre, single-arm, phase 1 trial. Lancet Haematol. 2023 Feb;10(2):e107-e116.

Nirav N. Shah, Amrita Y. Krishnan, Nina D. Shah, John M Burke, Jason M. Melear, Alexander I. Spira, Leslie L. Popplewell, Charalambos B. Andreadis, Saurabh Chhabra, Jeff P. Sharman, Jonathan L. Kaufman, Jonathon B. Cohen, Ruben Niesvizky, Thomas G. Martin, Clifford DiLea, Jason Kuriakose, Shannon L. Matheny, John P. Leonard, Arturo Molina; Preliminary Results of a Phase 1 Dose Escalation Study of the First-in-Class Anti-CD74 Antibody Drug Conjugate (ADC), STRO-001, in Patients with Advanced B-Cell Malignancies. Blood 2019; 134 (Supplement_1): 5329.

Amrita Y. Krishnan et al.. A phase 1 open-label, safety, pharmacokinetic, and preliminary efficacy study of STRO-001, an anti-CD74 antibody drug conjugate, in patients with advanced B-cell malignancies.. JCO 36, TPS7586-TPS7586(2018).

Dahlén, Eva, Niina Veitonmäki, and Per Norlén. “Bispecific antibodies in cancer immunotherapy.” Therapeutic advances in vaccines and immunotherapy 6.1 (2018): 3-17.7

Fan G, Wang Z, Hao M, Li J. Bispecific antibodies and their applications. J Hematol Oncol. 2015 Dec 21;8:130.

Usmani SZ, Garfall AL, van de Donk NWCJ, Nahi H, San-Miguel JF, Oriol A, Rosinol L, Chari A, Bhutani M, Karlin L, Benboubker L, Pei L, Verona R, Girgis S, Stephenson T, Elsayed Y, Infante J, Goldberg JD, Banerjee A, Mateos MV, Krishnan A. Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study. Lancet. 2021 Aug 21;398(10301):665-674.

Katarzyna Karwacz, Andrea T. Hooper, Chao-Pei Betty Chang, Heike Krupka, Jeffrey Chou, Viola Lam, Ivana Djuretic, Javier Chaparro-Riggers, Puja Sapra; Abstract 4557: BCMA-CD3 bispecific antibody PF-06863135: Preclinical rationale for therapeutic combinations. Cancer Res 15 August 2020; 80 (16_Supplement): 4557.

Bahlis NJ, Costello CL, Raje NS, Levy MY, Dholaria B, Solh M, Tomasson MH, Damore MA, Jiang S, Basu C, Skoura A, Chan EM, Trudel S, Jakubowiak A, Gasparetto C, Chu MP, DalovisioA, Sebag M, Lesokhin AM. Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial. Nat Med. 2023 Oct;29(10):2570-2576.

Nizar Jacques Bahlis, Michael H. Tomasson, Mohamad Mohty, Ruben Niesvizky, Ajay K. Nooka, Salomon Manier, Christopher Maisel, Yogesh Jethava, Joaquin Martinez-Lopez, H Miles Prince, Bertrand Arnulf, Paula Rodriguez Otero, Guenther Koehne, Cyrille Touzeau, Noopur Raje, Shinsuke Iida, Marc-Steffen Raab, Eric Leip, Sharon Sullivan, Umberto Conte, Andrea Viqueira, Alexander M Lesokhin; Efficacy and Safety of Elranatamab in Patients with Relapsed/Refractory Multiple Myeloma Naïve to B-Cell Maturation.

Dennis Cooper, Deepu Madduri, Suzanne Lentzsch, Sundar Jagannath, Jingjin Li, Anita Boyapati, Lieve Adriaens, Dhruti Chokshi, Min Zhu, Israel Lowy, David M. Weinreich, George D. Yancopoulos, Manish Sharma, Maria Karasarides, David Sternberg, Safety and Preliminary Clinical Activity of REGN5458, an Anti-Bcma x Anti-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma. Blood. 134(1), 3176.

Lee HC, Bumma N, Richter J, Dhodapkar M, Hoffman JE, Suvannasankha A, Zonder J, Shah MR, Lentzsch S, Maly JJ, Ye JC, Wu KL, Deveaux M, Chokshi D, Boyapati A, Hazra A, Lorenc KR, Kroog G, Houvras Y, Jagannath S. S197: Lınker-mm1 study: lınvoseltamab (regn5458) ınpatıentswıth relapsed/refractory multıple myeloma. Hemasphere. 2023 Aug 8;7(Suppl ):e1610068.

Seckinger A, Delgado JA, Moser S, Moreno L, Neuber B, Grab A, Lipp S, Merino J, Prosper F, Emde M, Delon C, Latzko M, Gianotti R, Lüoend R, Murr R, Hosse RJ, Harnisch LJ, Bacac M, Fauti T, Klein C, Zabaleta A, Hillengass J, Cavalcanti-Adam EA, Ho AD, Hundemer M, San Miguel JF, Strein K, Umaña P, Hose D, Paiva B, Vu MD. Target Expression, Generation, Preclinical Activity, and Pharmacokinetics of the BCMA-T Cell Bispecific Antibody EM801 for Multiple Myeloma Treatment. Cancer Cell. 2017 Mar 13;31(3):396410.

Prager I, Watzl C. Mechanisms of natural killer cell-mediated cellular cytotoxicity. J Leukoc Biol. 2019 Jun;105(6):1319-1329.

Plesner T, Harrison SJ, Quach H, Lee C, Bryant A, Vangsted A, Estell J, Delforge M, Offner F, Twomey P, Choeurng V, Li J, Hendricks R, Ruppert SM, Sumiyoshi T, Miller K, Cho E, Schjesvold F. Phase I Study of Safety and Pharmacokinetics of RO7297089, an Anti-BCMA/CD16a Bispecific Antibody, in Patients with Relapsed, Refractory Multiple Myeloma. Clin Hematol Int. 2023 Mar;5(1):43-51.

Nath K, Costa BA, Mailankody S. GPRC5D as a novel immunotherapeutic target in multiple myeloma. Nat Rev Clin Oncol. 2023 May;20(5):281-282.

Atamaniuk J, Gleiss A, Porpaczy E, Kainz B, Grunt TW, Raderer M, Hilgarth B, Drach J, Ludwig H, Gisslinger H, Jaeger U, Gaiger A. Overexpression of G protein-coupled receptor 5D in the bone marrow is associated with poor prognosis in patients with multiple myeloma. Eur J Clin Invest. 2012 Sep;42(9):953-60.

Carolina D. Schinke et al. Pivotal phase 2 MonumenTAL-1 results of talquetamab (tal), a GPRC5DxCD3 bispecific antibody (BsAb), for relapsed/refractory multiple myeloma (RRMM). JCO 41, 8036-8036(2023).

Jan Eckmann, Tanja Fauti, Aintzane Zabaleta, Laura Blanco, Sahar Kassem, Nadege Carrié, Stefan Lorenz, Alejandro Carpy, Tony Christopeit, Georg Fertig, Luise Bernasconi, Marlene Biehl, Sarah Diggelmann, Melanie Knobloch, Maud Mayoux, Charles Dumontet, Bruno Paiva, Ludovic Martinet, Stéphane Leclair, Wei Xu, Christian Klein, Pablo Umaña; RG6234: A Novel 2:1 GPRC5D T Cell Bispecific Antibody Exhibits Best in Class Potential for the Treatment of Multiple Myeloma As a Monotherapy and in Combination. Blood 2022; 140 (Supplement 1): 2091–2092.

Iryna Dekhtiarenko, Iva Lelios, Jan Attig, Nassim Sleiman, Domenico Lazzaro, Emilie Schindler, Jan Eckmann, Pablo Umana, Wolfgang Jacob, Meike Schneider, Carmelo Carlo-Stella, Ann-Marie E Bröske; Intravenous and Subcutaneous Administration of RG6234, a Novel GPRC5DxCD3 T-Cell Engaging Bispecific Antibody, Is Highly Active in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Biomarker Results from a Phase I Study. Blood 2022; 140 (Supplement 1): 10137–10139.

Li J, Stagg NJ, Johnston J, Harris MJ, Menzies SA, DiCara D, Clark V, Hristopoulos M, Cook R, Slaga D, Nakamura R, McCarty L, Sukumaran S, Luis E, Ye Z, Wu TD, Sumiyoshi T, Danilenko D, Lee GY, Totpal K, Ellerman D, Hötzel I, James JR, Junttila TT. Membrane-Proximal Epitope Facilitates Efficient T Cell Synapse Formation by Anti-FcRH5/ CD3 and Is a Requirement for Myeloma Cell Killing. Cancer Cell. 2017 Mar 13;31(3):383395.

Adam D. Cohen, Simon J Harrison, Amrita Krishnan, Rafael Fonseca, Peter A Forsberg, Andrew Spencer, Jesus G. Berdeja, Jacob P. Laubach, Mengsong Li, VoleakChoeurng, Anjali Vaze, Divya Samineni, Teiko Sumiyoshi, James Cooper, Bernard M Fine, Suzanne Trudel; Initial Clinical Activity and Safety of BFCR4350A, a FcRH5/ CD3 T-Cell-Engaging Bispecific Antibody, in Relapsed/Refractory Multiple Myeloma. Blood 2020; 136 (Supplement 1): 42–43.

Prashant Kapoor, Don A. Stevens, Xavier Leleu, Karim Belhadj Merzoug, Lionel Karlin, Salomon Manier, Thomas Chalopin, Cyrille Hulin, Aurore Perrot, Jésus G Berdeja, Cristiana Costa Chase, Cyrille Touzeau, Philippe Moreau, Sanjay Mohan, Alexander Lesokhin, Carol Huff, David H. Vesole, Joshua Richter, Jeffrey Matous, Eileen Wolff, Tejas Shah, Jeppe Koch-Olsen, Andrew Garton, Vinu Menon, Sunitha Gn, Mario Perro, Eugene Zhukovsky, Cyril Konto, LidaPacaud, Mohamad Mohty; Dose Escalation of ISB 1342, a Novel CD38xCD3 Bispecific Antibody, in Patients with Relapsed / Refractory Multiple Myeloma (RRMM). Blood 2023; 142 (Supplement 1): 3339.

Xiaocheng Chen, Oi Kwan Wong, Leonard Post; Abstract 5385: Multiple modes of action of the CD38 x ICAM-1 bispecific antibody. Cancer Res 15 June 2022; 82 (12_Supplement): 5385

Khanam R, Ashruf OS, Waqar SHB, Shah Z, Batool S, Mehreen R, Pachika P, Roksana Z, Rehman MEU, Anwer F. The Role of Bispecific Antibodies in Relapsed Refractory Multiple Myeloma: A Systematic Review. Antibodies (Basel). 2023 May 29;12(2):38.

Wang X, Zhao A, Zhu J, Niu T. Efficacy and safety of bispecific antibodies therapy for relapsed or refractory multiple myeloma: a systematic review and meta-analysis of prospective clinical trials. Front Immunol. 2024 Feb 28;15:1348955.

Ryan Danis, David Yashar, Sean Bujarski, Scott Jew, Regina Swift, James RBerenson; Outcomes of Triple Class Refractory Multiple Myeloma Patients: A SingleCenter Retrospective Study. Blood 2023; 142 (Supplement 1): 3369.

Rendo MJ,et al. CAR T-Cell Therapy for Patients with Multiple Myeloma: CurrentEvidence and Challenges. Blood Lymphat Cancer. 2022 Aug 29;12:119-136.

Feins S,et al. An introduction to chimeric antigen receptor (CAR) T-cellimmunotherapy for human cancer. Am J Hematol (2019) 94(S1):S3–s9

Jayaraman J, et al. CAR-T design: Elements and their synergistic function. E Bio Medicine (2020) 58:102931.

Brudno JN, Kochenderfer JN. Recent advances in CAR T-cell toxicity:Mechanisms, manifestations and management. Blood Rev (2019) 34:45–55.

Garfall AL, et al. Chimeric antigen receptor T cells against CD19 for multiplemyeloma. N Engl J Med (2015) 373(11):1040–7.

Brudno JN, et al. T Cells genetically modified to express an anti-B-Cell maturationantigen chimeric antigen receptor cause remissions of poor-prognosis relapsedmultiple myeloma. J Clin Oncol (2018) 36(22):2267–80.

Munshi NC, et al. Idecabtagenevicleucel in relapsed and refractory multiplemyeloma. N Engl J Med (2021) 384(8):705–16.

Munshi NC, Anderson LD, Shah N, et al. IdecabtageneVicleucel in Relapsed andRefractory Multiple Myeloma. N Engl J Med. 2021;384(8):705– 716.

Paula Rodriguez-Otero, M.D., et al. Ide-cel or Standard Regimens in Relapsedand Refractory Multiple Myeloma N Engl J Med 2023;388:1002-1014.

Berdeja JG, et al. Ciltacabtageneautoleucel, a B-cell maturation antigen-directedchimeric antigen receptor T-cell therapy in patients with relapsed or refractorymultiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. Lancet.2021;398(10297):314–324.

Martin T, et al. CiltacabtageneAutoleucel, an Anti-B-cell Maturation AntigenChimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory MultipleMyeloma: CARTITUDE-1 2-Year Follow-Up. J Clin Oncol. 2022;JCO2200842.

Agha ME, et al. Cartitude-2 cohort b: Updated clinical data and biologicalcorrelative analyses of ciltacabtageneautoleucel in patients with multiple myelomaand early relapse after initial therapy. EuripeanHeamtol Assoc (2022) 6, 86–87.

Van de Donk N, et al.B07: Safety and efficacy of ciltacabtageneautoleucel, achimeric antigen receptor t-cell therapy directed against b-cell maturation antigen inpatients with multiple myeloma and early relapse after initial therapy: cartitude-2results. HemaSphere (2022) 6:9–10.

Einsele H, et al. P08: CARTITUDE-2 UPDATE: Ciltacabtageneautoleucel, a b-cell maturation antigen–directed chimeric antigen receptor T-cell therapy, inlenalidomide-refractory patients with progressive multiple myeloma after 1-3 priorlines of therapy. HemaSphere (2022)

Janssen research and development l. CARVYKTICARTITUDE-4 (MMY3002 )study (2022).

Huang H, et al. Phase I open-label single arm study of GPRC5D CAR T-cells(OriCAR-017) in patients with relapsed/ refractory multiple myeloma (POLARIS).

JClin Oncol (2022) Shah NN, Fry TJ. Mechanisms of resistance to CAR T cell therapy. Nat Rev ClinOncol (2019) 16(6):372–85.

Pont MJ, et al. g-secretase inhibition increases efficacy of BCMA-specificchimeric antigen receptor T cells in multiple myeloma. Blood (2019) 134(19):1585–97.

Raje NS, et al. Updated clinical and correlative results from the phase I CRB-402study of the BCMA-targeted CAR T cell therapy bb21217 in patients with relapsedand refractory multiple myeloma. Blood (2021) 138(Supplement 1):548.

Nina Shah,etal.Initial Results from a Phase 1 Clinical Study of bb21217, a Next-Generation Anti Bcma CAR T Therapy. Blood 2018; 132 (Supplement 1): 488.